A Dual-Action Peptide for Visceral Fat Reduction and Sleep Quality Enhancement in Obese Adults

Pep19 (DIIADDEPLT) is a novel, orally active peptide identified as an inverse agonist of the cannabinoid type 1 (CB1) receptor, showing promising dual-action benefits in metabolic health and sleep quality. In a 60-day, triple-blind, placebo-controlled clinical trial involving obese adults (BMI 30–35), daily supplementation with 5 mg Pep19 led to a significant 17% reduction in visceral fat without affecting lean mass. Additionally, both 2 mg and 5 mg doses improved sleep quality by up to 35%, alongside measurable reductions in waist circumference and body weight. The peptide was well tolerated, with no reported adverse effects, suggesting its potential as a safe and effective solution for managing abdominal obesity and enhancing quality of life.

Source: Pep19: A Novel Approach for Reducing Visceral Fat and Improving Sleep Quality in Obese Adults—Results From an Early‐Stage Clinical Trial – Heimann – 2025 – Diabetes/Metabolism Research and Reviews – Wiley Online Library